A leading R& D Biotech developing immunomodulatory drugs for the treatment of Autoimmune Diseases & Cancer. Innovoimmune Biotherapeutics, is developing proprietary oral small molecule immunomodulatory drugs targeting cytokine, chemokine and signal transduction pathways critical in the pathogenesis of Autoimmune Diseases and Cancer.
Innovimmune Biotherapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/innovimmune-biotherapeutics-inc-” connections=”true” suffix=””]
In July 2014, Innovimmune was awarded a $3 Mn, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the preclinical development. Prior this Innovimmune recieved several other NIH grants totalling nearly $1Mn for the development of its pipeline.